Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) — Working Capital to Net Assets Ratio
Xinxiang Tuoxin Pharmaceutical Co.Ltd. (301089) has a Working Capital to Net Assets ratio of 29.8% as of March 2026. Working capital of CN¥439.09 Million (current assets of CN¥580.41 Million minus current liabilities of CN¥141.32 Million) is measured against net assets of CN¥1.47 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See debt-free asset ratio of Xinxiang Tuoxin Pharmaceutical Co.Ltd. to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Xinxiang Tuoxin Pharmaceutical Co.Ltd. Working Capital to Net Assets (2019–2025)
This chart shows how Xinxiang Tuoxin Pharmaceutical Co.Ltd.'s Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the ratio stands at 29.8%, reflecting working capital of CN¥439.09 Million against net assets of CN¥1.47 Billion CNY. Check Xinxiang Tuoxin Pharmaceutical Co.Ltd. tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Xinxiang Tuoxin Pharmaceutical Co.Ltd. (2019–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Xinxiang Tuoxin Pharmaceutical Co.Ltd. from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Xinxiang Tuoxin Pharmaceutical Co.Ltd. market cap and net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 29.6% | CN¥438.98 Million | CN¥1.48 Billion | CN¥584.95 Million | CN¥145.97 Million | ▼ -3.4 pp |
| 2024 | 33.0% | CN¥511.69 Million | CN¥1.55 Billion | CN¥677.01 Million | CN¥165.32 Million | ▼ -6.2 pp |
| 2023 | 39.1% | CN¥627.66 Million | CN¥1.60 Billion | CN¥822.17 Million | CN¥194.51 Million | ▼ -3.7 pp |
| 2022 | 42.9% | CN¥590.04 Million | CN¥1.38 Billion | CN¥1.01 Billion | CN¥423.96 Million | ▼ -6.5 pp |
| 2021 | 49.4% | CN¥542.16 Million | CN¥1.10 Billion | CN¥796.76 Million | CN¥254.60 Million | ▲ +50.5 pp |
| 2020 | -1.1% | CN¥-5.59 Million | CN¥490.87 Million | CN¥414.91 Million | CN¥420.50 Million | ▲ +1.9 pp |
| 2019 | -3.1% | CN¥-11.78 Million | CN¥383.11 Million | CN¥310.29 Million | CN¥322.08 Million | — |